| Literature DB >> 24474759 |
Brian P Timko1, Manuel Arruebo, Sahadev A Shankarappa, J Brian McAlvin, Obiajulu S Okonkwo, Boaz Mizrahi, Cristina F Stefanescu, Leyre Gomez, Jia Zhu, Angela Zhu, Jesus Santamaria, Robert Langer, Daniel S Kohane.
Abstract
A reservoir that could be remotely triggered to release a drug would enable the patient or physician to achieve on-demand, reproducible, repeated, and tunable dosing. Such a device would allow precise adjustment of dosage to desired effect, with a consequent minimization of toxicity, and could obviate repeated drug administrations or device implantations, enhancing patient compliance. It should exhibit low off-state leakage to minimize basal effects, and tunable on-state release profiles that could be adjusted from pulsatile to sustained in real time. Despite the clear clinical need for a device that meets these criteria, none has been reported to date to our knowledge. To address this deficiency, we developed an implantable reservoir capped by a nanocomposite membrane whose permeability was modulated by irradiation with a near-infrared laser. Irradiated devices could exhibit sustained on-state drug release for at least 3 h, and could reproducibly deliver short pulses over at least 10 cycles, with an on/off ratio of 30. Devices containing aspart, a fast-acting insulin analog, could achieve glycemic control after s.c. implantation in diabetic rats, with reproducible dosing controlled by the intensity and timing of irradiation over a 2-wk period. These devices can be loaded with a wide range of drug types, and therefore represent a platform technology that might be used to address a wide variety of clinical indications.Entities:
Keywords: diabetes; ethylcellulose; gold; nanoshell; poly(n-isopropylacrylamide)
Mesh:
Year: 2014 PMID: 24474759 PMCID: PMC3910641 DOI: 10.1073/pnas.1322651111
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205